When your cholesterol stays high even after taking statins, bempedoic acid, a once-daily oral medication that lowers LDL cholesterol by blocking an enzyme in the liver. Also known as an ACLY inhibitor, it works differently than statins—targeting a step earlier in cholesterol production without entering muscle tissue, which means fewer muscle-related side effects. This makes it a practical option for people who can’t tolerate statins or need extra help getting their numbers down.
Bempedoic acid doesn’t work alone. It’s often paired with ezetimibe, another cholesterol-lowering pill, to give a stronger effect. Together, they can cut LDL by 30–40%, which is close to what moderate-dose statins do. Unlike statins, it doesn’t cause muscle pain or weakness in most people, making it a go-to for those who’ve had bad reactions before. It’s also been shown to reduce heart attacks and strokes in high-risk patients, especially those with a history of heart disease or genetic high cholesterol.
It’s not a magic bullet, though. You still need to eat well, move regularly, and take it every day. It’s not for everyone—people with severe liver problems or those already on certain other cholesterol drugs should check with their doctor first. But for many, it’s a real alternative that fills a gap left by statins. What’s interesting is how it fits into the bigger picture of heart health. It connects directly to other treatments like PCSK9 inhibitors, which are injectables, and to lifestyle changes that lower inflammation and improve artery function. It’s part of a shift away from one-size-fits-all approaches, toward smarter, layered strategies for long-term heart protection.
Below, you’ll find real-world insights from people who’ve used it, comparisons with other drugs, and updates on how it’s being studied for broader use. Whether you’re considering it for yourself or just trying to understand your options, this collection gives you the facts without the fluff.
Ezetimibe and bempedoic acid are oral, non-statin medications for lowering LDL cholesterol in people who can't tolerate statins. Both reduce heart risk, with ezetimibe being low-cost and bempedoic acid offering proven cardiovascular benefits.